Dosing & Uses
Dosage Forms & Strengths
tablet
- 10mg
- 25mg
- 50mg
- 75mg
- 100mg
- 150mg
Depression
100-200 mg PO qHS or divided q12hr
Up to 300 mg/day in severely ill
Renal Impairment
Supplemental dose not necessary in peritoneal or hemodialysis
Other Indications & Uses
Off-label: Postherpetic neuralgia, vulvodynia, eating disorder
Dosing considerations
Initial therapy may be administered in divided doses or a single daily dose
Dosage should be initiated at a lower level and increased according to tolerance and clinical response
Maintenance therapy may be given on a once-daily schedule for patient convenience and compliance
Treatment of patients requiring as much as 300 mg should generally be initiated in hospitals, where regular visits by the physician, skilled nursing care, and frequent electrocardiograms (ECGs) are available
The best available evidence of impending toxicity from very high doses is prolongation of the QRS or QT intervals on the ECG
Clinical symptoms of intolerance, especially drowsiness, dizziness, and postural hypotension, should also alert the physician to the need for reduction in dosage
Dosage Forms & Strengths
tablet
- 10mg
- 25mg
- 50mg
- 75mg
- 100mg
- 150mg
Adolescents
<12 years: Safety and efficacy not established
Initial: 25-50 mg PO qDay; may gradually increase if needed to 100 mg/day PO qDay or divided q8-12hr
Not to exceed 150 mg/day
Dosing considerations
Initial therapy may be administered in divided doses or a single daily dose
Dosage should be initiated at a lower level and increased according to tolerance and clinical response
Maintenance therapy may be given on a once-daily schedule for patient convenience and compliance
The best available evidence of impending toxicity from very high doses is prolongation of the QRS or QT intervals on the ECG
Clinical symptoms of intolerance, especially drowsiness, dizziness, and postural hypotension, should also alert the physician to the need for reduction in dosage
Depression
25-100 mg PO qHS or divided q12hr
Up to 150 mg/day in severely ill
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (18)
- disopyramide
desipramine and disopyramide both increase QTc interval. Contraindicated.
- eliglustat
desipramine increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive and intermediate metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors.
- ibutilide
desipramine and ibutilide both increase QTc interval. Contraindicated.
- indapamide
desipramine and indapamide both increase QTc interval. Contraindicated.
- iobenguane I 123
desipramine decreases effects of iobenguane I 123 by pharmacodynamic antagonism. Contraindicated. If clinically appropriate, discontinue drugs that decrease uptake of NE for at least 5 half-lives; may cause false-negative imaging results.
- isocarboxazid
isocarboxazid and desipramine both increase serotonin levels. Contraindicated.
- lomitapide
desipramine increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds.
- pentamidine
desipramine and pentamidine both increase QTc interval. Contraindicated.
- phenelzine
phenelzine and desipramine both increase serotonin levels. Contraindicated.
- pimozide
desipramine and pimozide both increase QTc interval. Contraindicated.
- procainamide
desipramine and procainamide both increase QTc interval. Contraindicated.
- procarbazine
procarbazine and desipramine both increase serotonin levels. Contraindicated. Combination is contraindicated within 2 weeks of MAOI use.
- quinidine
quinidine and desipramine both increase QTc interval. Contraindicated.
- safinamide
desipramine, safinamide. Either increases toxicity of the other by serotonin levels. Contraindicated. Concomitant use could result in life-threatening serotonin syndrome.
- selegiline
selegiline and desipramine both increase serotonin levels. Contraindicated. Concurrent use or use within 14 days of selegiline treatment is contraindicated
- sotalol
desipramine and sotalol both increase QTc interval. Contraindicated.
- thioridazine
thioridazine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated.
- tranylcypromine
tranylcypromine and desipramine both increase serotonin levels. Contraindicated.
Serious - Use Alternative (145)
- adagrasib
adagrasib, desipramine. Either increases effects of the other by QTc interval. Avoid or Use Alternate Drug. Each drug prolongs the QTc interval, which may increased the risk of Torsade de pointes, other serious arryhthmias, and sudden death. If coadministration unavoidable, more frequent monitoring is recommended for such patients.
- albuterol
desipramine, albuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- amiodarone
desipramine and amiodarone both increase QTc interval. Avoid or Use Alternate Drug.
- amitriptyline
amitriptyline and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
amitriptyline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - amoxapine
amoxapine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
amoxapine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - arformoterol
desipramine, arformoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- arsenic trioxide
desipramine and arsenic trioxide both increase QTc interval. Avoid or Use Alternate Drug.
- artemether
artemether and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- artemether/lumefantrine
artemether/lumefantrine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
desipramine and artemether/lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. - axitinib
desipramine increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with moderate CYP3A4 inhibitors, monitor closely and reduce dose if necessary .
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and desipramine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate
- benzphetamine
desipramine, benzphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- bosutinib
desipramine increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.
- buprenorphine
buprenorphine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine buccal
buprenorphine buccal and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine subdermal implant
buprenorphine subdermal implant and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
buprenorphine subdermal implant and desipramine both increase sedation. Avoid or Use Alternate Drug. Limit use to patients for whom alternative treatment options are inadequate - buprenorphine transdermal
buprenorphine transdermal and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- buprenorphine, long-acting injection
buprenorphine, long-acting injection and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- buspirone
desipramine and buspirone both increase serotonin levels. Avoid or Use Alternate Drug.
- calcium/magnesium/potassium/sodium oxybates
desipramine, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- chlorpromazine
chlorpromazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- citalopram
citalopram and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. Citalopram may increase TCA levels. Increased risk of serotonin syndrome or neuroleptic malignant syndrome. Potential risk for QT prolongation. ECG monitoring is recommended.
desipramine and citalopram both increase QTc interval. Avoid or Use Alternate Drug. - clarithromycin
desipramine and clarithromycin both increase QTc interval. Avoid or Use Alternate Drug.
- clomipramine
clomipramine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
clomipramine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - clonidine
desipramine decreases effects of clonidine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- cyclobenzaprine
desipramine and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.
- dacomitinib
dacomitinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities.
- desvenlafaxine
desipramine and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.
- dexfenfluramine
desipramine, dexfenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dexmethylphenidate
desipramine, dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextroamphetamine
desipramine, dextroamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dextromethorphan
desipramine and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.
- diethylpropion
desipramine, diethylpropion. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dobutamine
desipramine, dobutamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dofetilide
desipramine and dofetilide both increase QTc interval. Avoid or Use Alternate Drug.
dofetilide increases toxicity of desipramine by QTc interval. Avoid or Use Alternate Drug. - dolasetron
dolasetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- dopamine
desipramine, dopamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dopexamine
desipramine, dopexamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- dosulepin
desipramine and dosulepin both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug. - doxepin
desipramine and doxepin both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and doxepin both increase serotonin levels. Avoid or Use Alternate Drug. - dronedarone
desipramine and dronedarone both increase QTc interval. Avoid or Use Alternate Drug.
- droperidol
desipramine and droperidol both increase QTc interval. Avoid or Use Alternate Drug.
- duloxetine
duloxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- eliglustat
desipramine increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .
- encorafenib
encorafenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- ephedrine
desipramine, ephedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- epinephrine
epinephrine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine, epinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - epinephrine racemic
epinephrine racemic and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine, epinephrine racemic. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - erythromycin base
desipramine and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin ethylsuccinate
desipramine and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin lactobionate
desipramine and erythromycin lactobionate both increase QTc interval. Avoid or Use Alternate Drug.
- erythromycin stearate
desipramine and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.
- escitalopram
escitalopram and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- fenfluramine
desipramine, fenfluramine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- fexinidazole
fexinidazole and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.
- fluconazole
desipramine and fluconazole both increase QTc interval. Avoid or Use Alternate Drug.
- fluoxetine
fluoxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
fluoxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - fluphenazine
fluphenazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- fluvoxamine
fluvoxamine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- formoterol
desipramine and formoterol both increase QTc interval. Avoid or Use Alternate Drug.
desipramine, formoterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. - fosamprenavir
fosamprenavir increases levels of desipramine by decreasing metabolism. Avoid or Use Alternate Drug.
- givosiran
givosiran will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.
- granisetron
granisetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
granisetron and desipramine both increase QTc interval. Avoid or Use Alternate Drug. - guanfacine
desipramine decreases effects of guanfacine by Other (see comment). Avoid or Use Alternate Drug. Comment: Inhibition of uptake by adrenergic neurons.
- haloperidol
haloperidol will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
desipramine and haloperidol both increase QTc interval. Avoid or Use Alternate Drug. - hydroxychloroquine sulfate
hydroxychloroquine sulfate and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- imipramine
desipramine and imipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and imipramine both increase serotonin levels. Avoid or Use Alternate Drug. - iobenguane I 131
desipramine will decrease the level or effect of iobenguane I 131 by Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose.
- isoproterenol
desipramine, isoproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ivosidenib
ivosidenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.
- ketoconazole
desipramine and ketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- lefamulin
lefamulin and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- levalbuterol
desipramine, levalbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- levoketoconazole
desipramine and levoketoconazole both increase QTc interval. Avoid or Use Alternate Drug.
- levomilnacipran
levomilnacipran and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- linezolid
linezolid and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.
- lisdexamfetamine
desipramine, lisdexamfetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- lofepramine
desipramine and lofepramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug. - lorcaserin
desipramine and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.
- lumefantrine
lumefantrine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
desipramine and lumefantrine both increase QTc interval. Avoid or Use Alternate Drug. - macimorelin
macimorelin and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.
- maprotiline
desipramine and maprotiline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug. - meperidine
desipramine and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.
- metaproterenol
desipramine, metaproterenol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methamphetamine
desipramine, methamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methylene blue
methylene blue and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.
- methylenedioxymethamphetamine
desipramine, methylenedioxymethamphetamine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- metoclopramide intranasal
desipramine, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- midodrine
desipramine, midodrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- milnacipran
milnacipran and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- mirtazapine
mirtazapine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- mobocertinib
mobocertinib and desipramine both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.
- moxifloxacin
desipramine and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.
- nefazodone
nefazodone and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- netupitant/palonosetron
netupitant/palonosetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- nilotinib
desipramine and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.
- norepinephrine
desipramine, norepinephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- nortriptyline
desipramine and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - octreotide
desipramine and octreotide both increase QTc interval. Avoid or Use Alternate Drug.
- octreotide (Antidote)
desipramine and octreotide (Antidote) both increase QTc interval. Avoid or Use Alternate Drug.
- olopatadine intranasal
desipramine and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- ondansetron
desipramine and ondansetron both increase QTc interval. Avoid or Use Alternate Drug. Avoid with congenital long QT syndrome; ECG monitoring recommended with concomitant medications that prolong QT interval, electrolyte abnormalities, CHF, or bradyarrhythmias.
ondansetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. - ozanimod
ozanimod increases toxicity of desipramine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Because the active metabolite of ozanimod inhibits MAO-B in vitro, there is a potential for serious adverse reactions, including hypertensive crisis. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Monitor for hypertension with concomitant use.
- palonosetron
palonosetron, desipramine. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.
- panobinostat
desipramine and panobinostat both increase QTc interval. Avoid or Use Alternate Drug.
- paroxetine
paroxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
paroxetine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - perphenazine
perphenazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- phendimetrazine
desipramine, phendimetrazine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phentermine
desipramine, phentermine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine
desipramine, phenylephrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
desipramine, phenylephrine PO. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pirbuterol
desipramine, pirbuterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- pitolisant
desipramine decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
- promazine
promazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- propylhexedrine
desipramine, propylhexedrine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- protriptyline
desipramine and protriptyline both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and protriptyline both increase serotonin levels. Avoid or Use Alternate Drug. - pseudoephedrine
desipramine increases effects of pseudoephedrine by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- quinidine
quinidine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.
- rasagiline
rasagiline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. Severe CNS toxicity associated with hyperpyrexia has been reported with the combined treatment of an antidepressant and rasagiline. Avoid combination within 14 days of MAOI use.
- ribociclib
ribociclib increases toxicity of desipramine by QTc interval. Avoid or Use Alternate Drug.
- salmeterol
desipramine, salmeterol. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- selegiline transdermal
selegiline transdermal and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- selinexor
selinexor, desipramine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- serdexmethylphenidate/dexmethylphenidate
desipramine, serdexmethylphenidate/dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- sertraline
sertraline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
desipramine and sertraline both increase QTc interval. Avoid or Use Alternate Drug. - sodium oxybate
desipramine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- St John's Wort
desipramine and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.
- tedizolid
tedizolid, desipramine. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.
- terbutaline
desipramine, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- thioridazine
thioridazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- toremifene
desipramine and toremifene both increase QTc interval. Avoid or Use Alternate Drug. Concurrent use of toremifene with agents causing QT prolongation should be avoided. If concomitant use is required it's recommended that toremifene be interrupted. If interruption not possible, patients requiring therapy with a drug that prolongs QT should be closely monitored. ECGs should be obtained for high risk patients.
- trazodone
desipramine and trazodone both increase QTc interval. Avoid or Use Alternate Drug.
trazodone and desipramine both increase serotonin levels. Avoid or Use Alternate Drug. - trifluoperazine
trifluoperazine and desipramine both increase QTc interval. Avoid or Use Alternate Drug.
- trimipramine
desipramine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug.
desipramine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug. - umeclidinium bromide/vilanterol inhaled
desipramine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.
desipramine and umeclidinium bromide/vilanterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated - vandetanib
desipramine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.
- vemurafenib
vemurafenib and desipramine both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.
- venlafaxine
venlafaxine and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.
- vilanterol/fluticasone furoate inhaled
desipramine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated
desipramine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. - vilazodone
desipramine, vilazodone. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug. Concomitant therapy should be discontinued immediately if signs or symptoms of serotonin syndrome emerge and supportive symptomatic treatment should be initiated. .
- vortioxetine
desipramine, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.
- xylometazoline
desipramine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- yohimbe
yohimbe, desipramine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.
- yohimbine
desipramine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- ziprasidone
desipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.
Monitor Closely (354)
- 5-HTP
desipramine and 5-HTP both increase serotonin levels. Modify Therapy/Monitor Closely.
- abiraterone
abiraterone increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Avoid coadministration of abiraterone with substrates of CYP2D6. If alternative therapy cannot be used, exercise caution and consider a dose reduction of the CYP2D6 substrate.
- abobotulinumtoxinA
abobotulinumtoxinA increases effects of desipramine by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects. .
- aclidinium
aclidinium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- acrivastine
acrivastine and desipramine both increase sedation. Use Caution/Monitor.
- albuterol
desipramine increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
albuterol and desipramine both increase QTc interval. Use Caution/Monitor. - alfentanil
alfentanil and desipramine both increase sedation. Use Caution/Monitor.
- alfuzosin
desipramine and alfuzosin both increase QTc interval. Use Caution/Monitor.
alfuzosin and desipramine both increase QTc interval. Use Caution/Monitor. - almotriptan
almotriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- alprazolam
alprazolam and desipramine both increase sedation. Use Caution/Monitor.
- amifampridine
desipramine increases toxicity of amifampridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Amifampridine can cause seizures. Coadministration with drugs that lower seizure threshold may increase this risk.
- amiodarone
amiodarone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- amisulpride
desipramine and amisulpride both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended if coadministered.
amisulpride and desipramine both increase sedation. Use Caution/Monitor. - amitriptyline
amitriptyline and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amitriptyline and desipramine both increase sedation. Use Caution/Monitor. - amobarbital
amobarbital and desipramine both increase sedation. Use Caution/Monitor.
- amoxapine
amoxapine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
amoxapine and desipramine both increase sedation. Use Caution/Monitor. - anagrelide
anagrelide and desipramine both increase QTc interval. Use Caution/Monitor.
- apomorphine
desipramine and apomorphine both increase sedation. Use Caution/Monitor.
apomorphine and desipramine both increase QTc interval. Use Caution/Monitor. - arformoterol
desipramine increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
arformoterol and desipramine both increase QTc interval. Use Caution/Monitor. - aripiprazole
aripiprazole and desipramine both increase sedation. Use Caution/Monitor.
aripiprazole and desipramine both increase QTc interval. Use Caution/Monitor. - armodafinil
desipramine increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
asenapine and desipramine both increase QTc interval. Use Caution/Monitor.
asenapine and desipramine both increase sedation. Use Caution/Monitor. - asenapine transdermal
asenapine transdermal and desipramine both increase QTc interval. Use Caution/Monitor.
asenapine transdermal and desipramine both increase sedation. Use Caution/Monitor. - atazanavir
atazanavir increases levels of desipramine by unspecified interaction mechanism. Use Caution/Monitor.
- atomoxetine
atomoxetine and desipramine both increase QTc interval. Use Caution/Monitor.
- atropine IV/IM
atropine IV/IM and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- avapritinib
avapritinib and desipramine both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and desipramine both increase sedation. Use Caution/Monitor.
- azithromycin
desipramine and azithromycin both increase QTc interval. Use Caution/Monitor.
- baclofen
baclofen and desipramine both increase sedation. Use Caution/Monitor.
- bedaquiline
desipramine and bedaquiline both increase QTc interval. Modify Therapy/Monitor Closely. ECG should be monitored closely
- belladonna and opium
belladonna and opium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
belladonna and opium and desipramine both increase sedation. Use Caution/Monitor. - benperidol
benperidol and desipramine both increase sedation. Use Caution/Monitor.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- benzphetamine
desipramine increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- brexpiprazole
desipramine will increase the level or effect of brexpiprazole by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor.
brexpiprazole and desipramine both increase sedation. Use Caution/Monitor. - brimonidine
brimonidine and desipramine both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and desipramine both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and desipramine both increase sedation. Use Caution/Monitor.
- buprenorphine
buprenorphine and desipramine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
buprenorphine buccal and desipramine both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
desipramine, buprenorphine subdermal implant. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
- buprenorphine, long-acting injection
desipramine, buprenorphine, long-acting injection. Either increases toxicity of the other by serotonin levels. Use Caution/Monitor. Concomitant use could result in life-threatening serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation, and during dose adjustment of the serotonergic drug. Discontinue buprenorphine if serotonin syndrome is suspected.
- bupropion
bupropion will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
desipramine increases toxicity of bupropion by unspecified interaction mechanism. Use Caution/Monitor. May lower seizure threshold; keep bupropion dose as low as possible. - butabarbital
butabarbital and desipramine both increase sedation. Use Caution/Monitor.
- butalbital
butalbital and desipramine both increase sedation. Use Caution/Monitor.
- butorphanol
butorphanol and desipramine both increase sedation. Use Caution/Monitor.
- caffeine
desipramine increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and desipramine both increase sedation. Use Caution/Monitor.
- carisoprodol
carisoprodol and desipramine both increase sedation. Use Caution/Monitor.
- celecoxib
celecoxib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- cenobamate
cenobamate, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor.
- ceritinib
ceritinib and desipramine both increase QTc interval. Use Caution/Monitor.
- chloral hydrate
chloral hydrate and desipramine both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
chlordiazepoxide and desipramine both increase sedation. Use Caution/Monitor.
- chloroquine
chloroquine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
chloroquine increases toxicity of desipramine by QTc interval. Use Caution/Monitor. - chlorpheniramine
chlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.
- chlorpromazine
chlorpromazine and desipramine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
chlorzoxazone and desipramine both increase sedation. Use Caution/Monitor.
- cimetidine
cimetidine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- cinnarizine
cinnarizine and desipramine both increase sedation. Use Caution/Monitor.
- cisapride
desipramine and cisapride both increase QTc interval. Use Caution/Monitor.
- clemastine
clemastine and desipramine both increase sedation. Use Caution/Monitor.
- clobazam
clobazam will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Lower doses of drugs metabolized by CYP2D6 may be required when used concomitantly.
desipramine, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression). - clomipramine
clomipramine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
clomipramine and desipramine both increase sedation. Use Caution/Monitor. - clonazepam
clonazepam and desipramine both increase sedation. Use Caution/Monitor.
- clorazepate
clorazepate and desipramine both increase sedation. Use Caution/Monitor.
- clozapine
clozapine and desipramine both increase sedation. Use Caution/Monitor.
clozapine and desipramine both increase QTc interval. Use Caution/Monitor. - cobicistat
cobicistat will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Carefully titrate antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitoring for antidepressant response
cobicistat will increase the level or effect of desipramine by Other (see comment). Use Caution/Monitor. Carefully titrate dose of the antidepressant to the desired effect, including using the lowest feasible initial or maintenance dose, and monitor its response during coadministration with TCAs and cobicistat. - cocaine topical
desipramine and cocaine topical both increase serotonin levels. Modify Therapy/Monitor Closely.
- codeine
codeine and desipramine both increase sedation. Use Caution/Monitor.
desipramine decreases effects of codeine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Prevents conversion of codeine to its active metabolite morphine. - crizotinib
crizotinib and desipramine both increase QTc interval. Use Caution/Monitor. ECG monitoring is recommended, along with drugs that may prolong the QT interval.
- cyclizine
cyclizine and desipramine both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
cyclobenzaprine and desipramine both increase sedation. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and desipramine both increase sedation. Use Caution/Monitor.
- dantrolene
dantrolene and desipramine both increase sedation. Use Caution/Monitor.
- daridorexant
desipramine and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darifenacin
darifenacin will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- dasatinib
desipramine and dasatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- debrisoquine
desipramine decreases effects of debrisoquine by Other (see comment). Use Caution/Monitor. Comment: Inhibition of uptake by adrenergic neurons.
- degarelix
degarelix and desipramine both increase QTc interval. Use Caution/Monitor.
- desflurane
desflurane and desipramine both increase sedation. Use Caution/Monitor.
desflurane and desipramine both increase QTc interval. Use Caution/Monitor. - desvenlafaxine
desvenlafaxine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg
- deutetrabenazine
desipramine and deutetrabenazine both increase sedation. Use Caution/Monitor.
deutetrabenazine and desipramine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). - dexchlorpheniramine
dexchlorpheniramine and desipramine both increase sedation. Use Caution/Monitor.
- dexfenfluramine
desipramine increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine and dexfenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely. - dexmedetomidine
dexmedetomidine and desipramine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
desipramine increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
desipramine increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine and dextroamphetamine both increase serotonin levels. Modify Therapy/Monitor Closely.
desipramine increases effects of dextroamphetamine by unknown mechanism. Use Caution/Monitor. - dextroamphetamine transdermal
desipramine will increase the level or effect of dextroamphetamine transdermal by pharmacodynamic synergism. Modify Therapy/Monitor Closely. May enhance the activity of tricyclic or sympathomimetic agents causing striking and sustained increases in dextroamphetamine levels in brain; May be potentiate cardiovascular effects. Monitor frequently and adjust or use an alternant based on clinical response.
- dextromoramide
dextromoramide and desipramine both increase sedation. Use Caution/Monitor.
- diamorphine
diamorphine and desipramine both increase sedation. Use Caution/Monitor.
- diazepam
diazepam and desipramine both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, desipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- diethylpropion
desipramine increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and desipramine both increase sedation. Use Caution/Monitor.
- difenoxin hcl
difenoxin hcl and desipramine both increase sedation. Use Caution/Monitor.
- dihydroergotamine
desipramine and dihydroergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- dihydroergotamine intranasal
desipramine and dihydroergotamine intranasal both increase serotonin levels. Modify Therapy/Monitor Closely.
- dimenhydrinate
dimenhydrinate and desipramine both increase sedation. Use Caution/Monitor.
- diphenhydramine
diphenhydramine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
diphenhydramine and desipramine both increase sedation. Use Caution/Monitor. - diphenoxylate hcl
diphenoxylate hcl and desipramine both increase sedation. Use Caution/Monitor.
- dipipanone
dipipanone and desipramine both increase sedation. Use Caution/Monitor.
- dobutamine
desipramine increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dolasetron
desipramine and dolasetron both increase QTc interval. Modify Therapy/Monitor Closely.
- donepezil
donepezil and desipramine both increase QTc interval. Use Caution/Monitor.
- dopamine
desipramine increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
desipramine increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
desipramine and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and dosulepin both increase sedation. Use Caution/Monitor. - doxepin
desipramine and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and doxepin both increase sedation. Use Caution/Monitor. - doxylamine
doxylamine and desipramine both increase sedation. Use Caution/Monitor.
- dronedarone
dronedarone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- droperidol
droperidol and desipramine both increase sedation. Use Caution/Monitor.
- duloxetine
duloxetine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- efavirenz
efavirenz and desipramine both increase QTc interval. Use Caution/Monitor.
- eletriptan
eletriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- eliglustat
eliglustat increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect.
eliglustat and desipramine both increase QTc interval. Use Caution/Monitor. - elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events.
- entrectinib
entrectinib and desipramine both increase QTc interval. Use Caution/Monitor.
- ephedrine
desipramine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine increases effects of ephedrine by unknown mechanism. Use Caution/Monitor. - epinephrine
desipramine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine increases effects of epinephrine by unknown mechanism. Use Caution/Monitor. - epinephrine inhaled
desipramine and epinephrine inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Tricyclic antidepressants may potentiate epinephrine effect on cardiovascular system.
- epinephrine racemic
desipramine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine increases effects of epinephrine racemic by unknown mechanism. Use Caution/Monitor. - ergotamine
desipramine and ergotamine both increase serotonin levels. Modify Therapy/Monitor Closely.
- eribulin
eribulin and desipramine both increase QTc interval. Use Caution/Monitor.
- escitalopram
escitalopram increases toxicity of desipramine by QTc interval. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, desipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
estazolam and desipramine both increase sedation. Use Caution/Monitor.
- ethanol
desipramine and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and desipramine both increase sedation. Use Caution/Monitor.
- ezogabine
ezogabine, desipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.
- fedratinib
fedratinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary.
- fenfluramine
desipramine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine and fenfluramine both increase serotonin levels. Modify Therapy/Monitor Closely.
fenfluramine, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome. - fingolimod
fingolimod and desipramine both increase QTc interval. Use Caution/Monitor.
- flecainide
desipramine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.
- fluoxetine
desipramine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- fluphenazine
fluphenazine and desipramine both increase sedation. Use Caution/Monitor.
- flurazepam
flurazepam and desipramine both increase sedation. Use Caution/Monitor.
- fluvoxamine
fluvoxamine and desipramine both increase QTc interval. Modify Therapy/Monitor Closely.
- formoterol
desipramine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- foscarnet
desipramine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.
- fostemsavir
desipramine and fostemsavir both increase QTc interval. Use Caution/Monitor. QTc prolongation reported with higher than recommended doses of fostemsavir.
- frovatriptan
frovatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- gabapentin
gabapentin, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
desipramine and ganaxolone both increase sedation. Use Caution/Monitor.
- gemifloxacin
gemifloxacin and desipramine both increase QTc interval. Use Caution/Monitor.
- gilteritinib
gilteritinib and desipramine both increase QTc interval. Use Caution/Monitor.
- glycopyrrolate
desipramine increases levels of glycopyrrolate by unknown mechanism. Use Caution/Monitor.
- glycopyrrolate inhaled
desipramine increases levels of glycopyrrolate inhaled by unknown mechanism. Use Caution/Monitor.
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, desipramine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- goserelin
desipramine and goserelin both increase QTc interval. Use Caution/Monitor.
- haloperidol
haloperidol and desipramine both increase sedation. Use Caution/Monitor.
- henbane
henbane and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- homatropine
homatropine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- huperzine A
huperzine A increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- hydrocodone
hydrocodone, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- hydromorphone
hydromorphone and desipramine both increase sedation. Use Caution/Monitor.
- hydroxyzine
hydroxyzine and desipramine both increase sedation. Use Caution/Monitor.
hydroxyzine and desipramine both increase QTc interval. Use Caution/Monitor. - hyoscyamine
hyoscyamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- hyoscyamine spray
hyoscyamine spray and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- ibrutinib
desipramine increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.
- iloperidone
desipramine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.
iloperidone and desipramine both increase sedation. Use Caution/Monitor. - imatinib
imatinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
desipramine will increase the level or effect of imatinib by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. - imipramine
desipramine and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and imipramine both increase sedation. Use Caution/Monitor. - indacaterol, inhaled
indacaterol, inhaled, desipramine. QTc interval. Use Caution/Monitor. Indacaterol should be administered with extreme caution to patients treated with TCAs. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.
- ipratropium
ipratropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.
- isoflurane
isoflurane and desipramine both increase QTc interval. Use Caution/Monitor.
- isoniazid
desipramine and isoniazid both increase serotonin levels. Modify Therapy/Monitor Closely.
- isoproterenol
desipramine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- itraconazole
itraconazole and desipramine both increase QTc interval. Use Caution/Monitor.
- ketamine
ketamine and desipramine both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
desipramine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- L-tryptophan
desipramine and L-tryptophan both increase serotonin levels. Modify Therapy/Monitor Closely.
- lapatinib
desipramine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.
- lasmiditan
lasmiditan, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
desipramine increases effects of lasmiditan by serotonin levels. Use Caution/Monitor. Coadministration may increase risk of serotonin syndrome. - lemborexant
lemborexant, desipramine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
desipramine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levofloxacin
desipramine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- levorphanol
levorphanol and desipramine both increase sedation. Use Caution/Monitor.
- levothyroxine
levothyroxine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- liothyronine
liothyronine increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- liotrix
liotrix increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- lisdexamfetamine
desipramine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine, lisdexamfetamine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue along with concomitant serotonergic drug(s). - lithium
desipramine and lithium both increase serotonin levels. Modify Therapy/Monitor Closely.
lithium and desipramine both increase QTc interval. Use Caution/Monitor. - lofepramine
desipramine and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and lofepramine both increase sedation. Use Caution/Monitor. - lofexidine
desipramine and lofexidine both increase sedation. Use Caution/Monitor.
desipramine decreases effects of lofexidine by unspecified interaction mechanism. Use Caution/Monitor. - loprazolam
loprazolam and desipramine both increase sedation. Use Caution/Monitor.
- lorazepam
lorazepam and desipramine both increase sedation. Use Caution/Monitor.
- lorcaserin
lorcaserin will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- lormetazepam
lormetazepam and desipramine both increase sedation. Use Caution/Monitor.
- loxapine
loxapine and desipramine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
loxapine inhaled and desipramine both increase sedation. Use Caution/Monitor.
- lsd
desipramine and lsd both increase serotonin levels. Modify Therapy/Monitor Closely.
- lurasidone
lurasidone increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Potential for increased risk of hypotension with concurrent use. Monitor blood pressure and adjust dose of antihypertensive agent as needed.
- maprotiline
desipramine and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and maprotiline both increase sedation. Use Caution/Monitor. - maraviroc
maraviroc will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- marijuana
marijuana will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
desipramine and marijuana both increase sedation. Use Caution/Monitor. - meclizine
meclizine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- melatonin
desipramine and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
meperidine and desipramine both increase sedation. Use Caution/Monitor.
- meprobamate
desipramine and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
desipramine increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
metaxalone and desipramine both increase sedation. Use Caution/Monitor.
- methadone
desipramine and methadone both increase QTc interval. Modify Therapy/Monitor Closely.
methadone and desipramine both increase sedation. Use Caution/Monitor. - methamphetamine
desipramine increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
methocarbamol and desipramine both increase sedation. Use Caution/Monitor.
- methscopolamine
methscopolamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- methylenedioxymethamphetamine
desipramine increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methylphenidate
desipramine, methylphenidate. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- methylphenidate transdermal
methylphenidate transdermal will increase the level or effect of desipramine by decreasing elimination. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.
- midazolam
midazolam and desipramine both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
desipramine increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mifepristone
mifepristone, desipramine. QTc interval. Modify Therapy/Monitor Closely. Use alternatives if available.
- mirabegron
mirabegron will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- mirtazapine
desipramine and mirtazapine both increase sedation. Use Caution/Monitor.
desipramine and mirtazapine both increase serotonin levels. Modify Therapy/Monitor Closely. - modafinil
desipramine increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
morphine and desipramine both increase sedation. Use Caution/Monitor.
desipramine and morphine both increase serotonin levels. Modify Therapy/Monitor Closely. - motherwort
desipramine and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
desipramine and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
desipramine and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
nalbuphine and desipramine both increase sedation. Use Caution/Monitor.
- naldemedine
desipramine increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with strong or moderate CYP3A4 inhibitors.
- naratriptan
naratriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- nefopam
nefopam, desipramine. Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Use combination with caution.
- nelfinavir
nelfinavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- nilotinib
nilotinib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- norepinephrine
desipramine increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
desipramine increases effects of norepinephrine by unknown mechanism. Use Caution/Monitor. - nortriptyline
desipramine and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and nortriptyline both increase sedation. Use Caution/Monitor. - ofloxacin
desipramine and ofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.
- olanzapine
olanzapine and desipramine both increase sedation. Use Caution/Monitor.
olanzapine and desipramine both increase QTc interval. Use Caution/Monitor. - oliceridine
desipramine, oliceridine. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely.
desipramine increases toxicity of oliceridine by Other (see comment). Modify Therapy/Monitor Closely. Comment: Anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. Monitor for signs of urinary retention or reduced gastric motility if oliceridine is coadministered with anticholinergics. - olodaterol inhaled
desipramine and olodaterol inhaled both increase QTc interval. Use Caution/Monitor. TCAs prolong the QTc interval and may potentiate the effects of beta2 agonists on the cardiovascular system; increased risk of ventricular arrhythmias
- opium tincture
opium tincture and desipramine both increase sedation. Use Caution/Monitor.
- orphenadrine
desipramine and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.
orphenadrine and desipramine both increase sedation. Use Caution/Monitor. - osilodrostat
osilodrostat and desipramine both increase QTc interval. Use Caution/Monitor.
- osimertinib
osimertinib and desipramine both increase QTc interval. Use Caution/Monitor. Conduct periodic monitoring with ECGs and electrolytes in patients taking drugs known to prolong the QTc interval.
- oxazepam
oxazepam and desipramine both increase sedation. Use Caution/Monitor.
- oxybutynin
oxybutynin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin topical
oxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxybutynin transdermal
oxybutynin transdermal and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- oxycodone
oxycodone and desipramine both increase sedation. Use Caution/Monitor.
- oxymetazoline intranasal
desipramine increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. TCAs inhibit norepinephrine uptake in adrenergic neurons, thereby increasing synaptic norepinephrine levels. Coadministration with alpha1 agonists may cause increased adrenergic receptor stimulation. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use alternant anesthetic in patients taking TCAs.
- oxymorphone
oxymorphone and desipramine both increase sedation. Use Caution/Monitor.
- ozanimod
ozanimod and desipramine both increase QTc interval. Modify Therapy/Monitor Closely. The potential additive effects on heart rate, treatment with ozanimod should generally not be initiated in patients who are concurrently treated with QT prolonging drugs with known arrhythmogenic properties.
- paliperidone
desipramine and paliperidone both increase QTc interval. Modify Therapy/Monitor Closely.
paliperidone and desipramine both increase sedation. Use Caution/Monitor. - pancuronium
pancuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- panobinostat
panobinostat will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Panobinostat can increase the levels and effects of sensitive CYP2D6 substrates or those with a narrow therapeutic index CYP2D6.
- papaveretum
papaveretum and desipramine both increase sedation. Use Caution/Monitor.
- papaverine
desipramine and papaverine both increase sedation. Use Caution/Monitor.
- parecoxib
parecoxib will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- paroxetine
desipramine and paroxetine both increase QTc interval. Modify Therapy/Monitor Closely.
- pasireotide
desipramine and pasireotide both increase QTc interval. Modify Therapy/Monitor Closely.
- pazopanib
desipramine and pazopanib both increase QTc interval. Use Caution/Monitor.
- peginterferon alfa 2b
peginterferon alfa 2b, desipramine. Other (see comment). Use Caution/Monitor. Comment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate.
- pentazocine
pentazocine and desipramine both increase sedation. Use Caution/Monitor.
desipramine and pentazocine both increase serotonin levels. Modify Therapy/Monitor Closely. - pentobarbital
pentobarbital and desipramine both increase sedation. Use Caution/Monitor.
- perphenazine
perphenazine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
perphenazine and desipramine both increase sedation. Use Caution/Monitor. - phendimetrazine
desipramine increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
phenobarbital and desipramine both increase sedation. Use Caution/Monitor.
- phentermine
desipramine increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
desipramine increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine ophthalmic
desipramine, phenylephrine ophthalmic. Other (see comment). Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.
- phenylephrine PO
desipramine increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
desipramine and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
pimozide and desipramine both increase sedation. Use Caution/Monitor.
- pirbuterol
desipramine increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- posaconazole
desipramine and posaconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- pralidoxime
pralidoxime and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- pregabalin
pregabalin, desipramine. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
primidone and desipramine both increase sedation. Use Caution/Monitor.
- prochlorperazine
prochlorperazine and desipramine both increase QTc interval. Use Caution/Monitor.
prochlorperazine and desipramine both increase sedation. Use Caution/Monitor. - promethazine
promethazine and desipramine both increase QTc interval. Use Caution/Monitor.
promethazine and desipramine both increase sedation. Use Caution/Monitor. - propafenone
propafenone will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- propantheline
propantheline and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- propofol
propofol and desipramine both increase sedation. Use Caution/Monitor.
- propylhexedrine
desipramine increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
desipramine and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and protriptyline both increase sedation. Use Caution/Monitor. - quazepam
quazepam and desipramine both increase sedation. Use Caution/Monitor.
- quetiapine
quetiapine and desipramine both increase sedation. Use Caution/Monitor.
quetiapine, desipramine. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Avoid use with drugs that prolong QT and in patients with risk factors for prolonged QT interval. Postmarketing cases show QT prolongation with overdose in patients with concomitant illness or with drugs known to cause electrolyte imbalance or prolong QT. - quinacrine
quinacrine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- quinine
desipramine and quinine both increase QTc interval. Use Caution/Monitor.
- ramelteon
desipramine and ramelteon both increase sedation. Use Caution/Monitor.
- ranolazine
ranolazine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
desipramine and ranolazine both increase QTc interval. Modify Therapy/Monitor Closely. - rapacuronium
rapacuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- remimazolam
remimazolam, desipramine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
- rifabutin
rifabutin decreases levels of desipramine by increasing metabolism. Use Caution/Monitor.
- rilpivirine
rilpivirine increases toxicity of desipramine by QTc interval. Use Caution/Monitor. Rilpivirine should be used with caution when co-administered with a drug with a known risk of Torsades de Pointes.
- risperidone
desipramine and risperidone both increase QTc interval. Modify Therapy/Monitor Closely.
risperidone and desipramine both increase sedation. Use Caution/Monitor. - ritonavir
ritonavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- rizatriptan
rizatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- rocuronium
rocuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- rolapitant
rolapitant will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration.
- romidepsin
desipramine and romidepsin both increase QTc interval. Modify Therapy/Monitor Closely.
- salmeterol
desipramine increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- SAMe
desipramine and SAMe both increase serotonin levels. Modify Therapy/Monitor Closely.
- scopolamine
scopolamine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- scullcap
desipramine and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
secobarbital and desipramine both increase sedation. Use Caution/Monitor.
- selpercatinib
selpercatinib increases toxicity of desipramine by QTc interval. Use Caution/Monitor.
- sertraline
sertraline will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely.
- sevoflurane
sevoflurane and desipramine both increase sedation. Use Caution/Monitor.
sevoflurane and desipramine both increase QTc interval. Use Caution/Monitor. - shepherd's purse
desipramine and shepherd's purse both increase sedation. Use Caution/Monitor.
- sodium sulfate/?magnesium sulfate/potassium chloride
sodium sulfate/?magnesium sulfate/potassium chloride increases effects of desipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.
- sodium sulfate/potassium sulfate/magnesium sulfate
sodium sulfate/potassium sulfate/magnesium sulfate increases effects of desipramine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.
- sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol
desipramine, sodium sulfate/potassium sulfate/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.
- solifenacin
solifenacin and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
solifenacin and desipramine both increase QTc interval. Use Caution/Monitor. - sorafenib
sorafenib and desipramine both increase QTc interval. Use Caution/Monitor.
- stiripentol
stiripentol, desipramine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sufentanil
sufentanil and desipramine both increase sedation. Use Caution/Monitor.
- sufentanil SL
sufentanil SL, desipramine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.
- sulfamethoxazole
desipramine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.
- sumatriptan
sumatriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- sumatriptan intranasal
sumatriptan intranasal and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
- suvorexant
suvorexant and desipramine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessary
- tacrolimus
desipramine and tacrolimus both increase QTc interval. Use Caution/Monitor.
- tamsulosin
desipramine increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dose reduction may be needed for coadministered drugs that are predominantly metabolized by CYP3A.
desipramine increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. - tapentadol
tapentadol and desipramine both increase sedation. Use Caution/Monitor.
desipramine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely. - telavancin
desipramine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.
- temazepam
temazepam and desipramine both increase sedation. Use Caution/Monitor.
- terbinafine
terbinafine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.
- terbutaline
desipramine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- tetrabenazine
tetrabenazine and desipramine both increase QTc interval. Use Caution/Monitor.
- thioridazine
thioridazine and desipramine both increase sedation. Use Caution/Monitor.
- thiothixene
thiothixene and desipramine both increase sedation. Use Caution/Monitor.
desipramine and thiothixene both increase QTc interval. Use Caution/Monitor. - thyroid desiccated
thyroid desiccated increases effects of desipramine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.
- tiotropium
tiotropium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- tipranavir
tipranavir will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
- tofacitinib
desipramine increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. No specific dose adjustment recommended when tofacitinib coadministered with moderate CYP3A4 inhibitors; decrease tofacitinib dose if coadministered with both moderate CYP3A4 and potent CYP2C19 inhibitors.
- tolterodine
tolterodine and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- topiramate
desipramine and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
tramadol and desipramine both increase sedation. Use Caution/Monitor.
desipramine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely. - trazodone
desipramine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and trazodone both increase sedation. Use Caution/Monitor. - triazolam
triazolam and desipramine both increase sedation. Use Caution/Monitor.
- triclofos
triclofos and desipramine both increase sedation. Use Caution/Monitor.
- trifluoperazine
trifluoperazine and desipramine both increase sedation. Use Caution/Monitor.
- trihexyphenidyl
trihexyphenidyl and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.
- trimethoprim
desipramine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.
- trimipramine
desipramine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
desipramine and trimipramine both increase sedation. Use Caution/Monitor. - triprolidine
triprolidine and desipramine both increase sedation. Use Caution/Monitor.
- tropisetron
desipramine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.
- trospium chloride
trospium chloride and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- valbenazine
valbenazine and desipramine both increase QTc interval. Use Caution/Monitor.
- valerian
valerian and desipramine both increase sedation. Use Caution/Monitor.
- vecuronium
vecuronium and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.
- venlafaxine
venlafaxine will increase the level or effect of desipramine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.
desipramine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely. - voclosporin
voclosporin, desipramine. Either increases effects of the other by QTc interval. Use Caution/Monitor.
- voriconazole
desipramine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.
- xylometazoline
desipramine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
desipramine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
desipramine and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
ziprasidone and desipramine both increase sedation. Use Caution/Monitor.
- zolmitriptan
zolmitriptan and desipramine both increase serotonin levels. Modify Therapy/Monitor Closely.
Minor (98)
- acarbose
desipramine increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
- amobarbital
amobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- anticholinergic/sedative combos
anticholinergic/sedative combos and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- atracurium
atracurium and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- atropine
atropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
desipramine increases levels of atropine by unknown mechanism. Minor/Significance Unknown. - atropine IV/IM
desipramine increases levels of atropine IV/IM by unknown mechanism. Minor/Significance Unknown.
- bazedoxifene/conjugated estrogens
bazedoxifene/conjugated estrogens, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- belladonna alkaloids
belladonna alkaloids and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- benztropine
benztropine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- bethanechol
bethanechol increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- brimonidine
desipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown.
- butabarbital
butabarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- butalbital
butalbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- carbachol
carbachol increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- carbamazepine
carbamazepine decreases levels of desipramine by increasing metabolism. Minor/Significance Unknown.
- cevimeline
cevimeline increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- chlorpromazine
desipramine, chlorpromazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, chlorpromazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - chlorpropamide
desipramine increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
- cisatracurium
cisatracurium and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- conjugated estrogens
conjugated estrogens, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- conjugated estrogens, vaginal
conjugated estrogens, vaginal, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- cyclizine
cyclizine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- cyclobenzaprine
cyclobenzaprine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- darifenacin
darifenacin and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- desflurane
desflurane, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- dexmethylphenidate
dexmethylphenidate increases effects of desipramine by decreasing metabolism. Minor/Significance Unknown.
- dicyclomine
dicyclomine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- diphenhydramine
diphenhydramine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
desipramine and diphenhydramine both decrease cholinergic effects/transmission. Minor/Significance Unknown. - donepezil
donepezil increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- echothiophate iodide
echothiophate iodide increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- estradiol
estradiol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens conjugated synthetic
estrogens conjugated synthetic, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- estrogens esterified
estrogens esterified, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens may inhibit hepatic metabolism of tricyclic antidepressants. However, interactions are not common.
- estropipate
estropipate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- ethanol
ethanol decreases levels of desipramine by increasing metabolism. Minor/Significance Unknown. Interaction esp. seen in detoxified alcoholics.
- ethinylestradiol
ethinylestradiol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Oxidative metabolism of TCAs may be decreased by ethinyl estradiol. Increased antidepressant serum concentrations may occur. Potential for increased TCA adverse effects.
- etomidate
etomidate, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- eucalyptus
desipramine and eucalyptus both increase sedation. Minor/Significance Unknown.
- fesoterodine
fesoterodine and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- flavoxate
flavoxate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- fluphenazine
desipramine, fluphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, fluphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - galantamine
galantamine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- glimepiride
desipramine increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
- glipizide
desipramine increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
- glyburide
desipramine increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
- glycopyrrolate
glycopyrrolate and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- glycopyrrolate inhaled
glycopyrrolate inhaled and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- hydroxyprogesterone caproate (DSC)
hydroxyprogesterone caproate (DSC), desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- insulin aspart
desipramine increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin detemir
desipramine increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glargine
desipramine increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin glulisine
desipramine increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin lispro
desipramine increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin NPH
desipramine increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
- insulin regular human
desipramine increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
- isoproterenol
isoproterenol, desipramine. Mechanism: unknown. Minor/Significance Unknown. Risk of cardiac arrhythmias.
- ketamine
ketamine, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- lithium
lithium, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Risk of neurotoxicity in geriatric pts. Multiple mechanisms involved.
- mestranol
mestranol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- metformin
desipramine increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
- miglitol
desipramine increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
- nateglinide
desipramine increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- neostigmine
neostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- onabotulinumtoxinA
onabotulinumtoxinA and desipramine both decrease cholinergic effects/transmission. Minor/Significance Unknown.
- panax ginseng
panax ginseng increases effects of desipramine by pharmacodynamic synergism. Minor/Significance Unknown.
- pentobarbital
pentobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- perphenazine
desipramine, perphenazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, perphenazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - phenobarbital
phenobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- physostigmine
physostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- pilocarpine
pilocarpine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- pioglitazone
desipramine increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- pleurisy root
pleurisy root decreases effects of desipramine by unspecified interaction mechanism. Minor/Significance Unknown. Theoretical interaction.
- primidone
primidone, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- prochlorperazine
desipramine, prochlorperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, prochlorperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - progesterone micronized
progesterone micronized, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Estrogens and progestins may decr tricyclic antidepressant effects, while increasing TCA plasma concentration and adverse effects.
- promazine
desipramine, promazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, promazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - promethazine
desipramine, promethazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, promethazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - propofol
propofol, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- pyridostigmine
pyridostigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- repaglinide
desipramine increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
- rivastigmine
rivastigmine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- rosiglitazone
desipramine increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
- sage
desipramine and sage both increase sedation. Minor/Significance Unknown.
- saxagliptin
desipramine increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- secobarbital
secobarbital, desipramine. Other (see comment). Minor/Significance Unknown. Comment: Barbiturates may increase adverse effects, including respiratory depression, produced by toxic doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and decrease blood concentrations of TCAs.
- serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate increases effects of desipramine by decreasing metabolism. Minor/Significance Unknown.
- sevoflurane
sevoflurane, desipramine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.
- sitagliptin
desipramine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- succinylcholine
succinylcholine increases and desipramine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Minor/Significance Unknown.
- sulfamethoxazole
sulfamethoxazole decreases levels of desipramine by unspecified interaction mechanism. Minor/Significance Unknown.
- thioridazine
desipramine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - tolazamide
desipramine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
- tolbutamide
desipramine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
- trifluoperazine
desipramine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects.
desipramine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects. - vasopressin
desipramine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.
- verapamil
verapamil increases levels of desipramine by decreasing metabolism. Minor/Significance Unknown.
- vildagliptin
desipramine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
- zolpidem
zolpidem, desipramine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.
Adverse Effects
Frequency Not Defined
Common
- Fatigue
- Lethargy
- Sedation
- Weakness
- Constipation
- Dry mouth
- Blurred vision
Less Common
- Agitation
- Anxiety
- Headache
- Insomnia
- Nausea
- Vomiting
- Sweating
Infrequent
- ECG changes, orthostatic hypotension, tachycardia
- Confusion, dizziness, paresthesia
- Extrapyramidal symptoms
- Rash
- Elevated LFTs
- Sexual dysfunction
- Tinnitus
Rare
- Seizure
- Agranulocytosis
- Eosinophilia
- Leukopenia
- Thrombocytopenia
- SIADH
Warnings
Black Box Warnings
In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 years) taking antidepressants for major depressive disorders and other psychiatric illnesses. This increase was not seen in patients aged >24 years. A slight decrease in suicidal thinking was seen in adults >65 years. In children and young adults, risks must be weighed against the benefits of taking antidepressants. Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies. This should be done during initial 1-2 months of therapy and dosage adjustments. The patient’s family should communicate any abrupt changes in behavior to the healthcare provider
Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy
This drug is not approved for use in pediatric patients
Contraindications
Hypersensitivity
Acute recovery post-MI
Within 14 days of taking MAO inhibitor
Cautions
Use caution in BPH and respiratory impairment
Risk of anticholinergic side effects
Clinical studies did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects; other reported clinical experience has not identified differences in responses between the elderly and younger patients
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function; because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function
Use caution in patients with cardiovascular disease, because of possibility of conduction defects, arrhythmias, tachycardias, strokes, and acute myocardial infarction
Caution in patients who have a family history of sudden death, cardiac dysrhythmias, or cardiac conduction disturbances
Use caution in patients with a history of urinary retention or glaucoma, because of the anticholinergic properties of the drug
Caution in patients with thyroid disease or those taking thyroid medication, because of possibility of cardiovascular toxicity, including arrhythmias
Caution in patients with a history of seizure disorder, because this drug has been shown to lower seizure threshold; seizures precede cardiac dysrhythmias and death in some patients
The pupillary dilation that occurs following use of many antidepressant drugs may trigger an angle-closure attack in a patient with anatomically narrow angles who does not have a patent iridectomy
The patient should be cautioned that this drug may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery
Coadministration with MAO inhibitors
- Risk of serotonin syndrome when coadministered within 14 days of MAOIs, or coadministered with other strong serotonergic drugs (eg, SNRIs, SSRIs)
- Starting desipramine in a patient who is being treated with linezolid or IV methylene blue is contraindicated because of an increased risk of serotonin syndrome
- If linezolid or IV methylene blue must be administered, discontinue desipramine immediately and monitor for CNS toxicity; may resume clomipramine 24 hr after last linezolid or methylene blue dose or after 2 weeks of monitoring, whichever comes first
Clinical worsening and suicide risk
- Patients with major depressive disorder (MDD), both adult and pediatric, may experience worsening of their depression and/or emergence of suicidal ideation and behavior (suicidality) or unusual changes in behavior, whether or not they are taking antidepressant medications, and this risk may persist until significant remission occurs
- Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide; there has been a long-standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment
- Pooled analyses of short-term placebo-controlled trials of antidepressant drugs (selective serotonin reuptake inhibitors [SSRIs] and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18 to 24) with major depressive disorder (MDD) and other psychiatric disorders
- Short-term studies did not show an increase in risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older
- It is unknown whether the suicidality risk extends to longer-term use, i.e., beyond several months. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression
- Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms
- Prescriptions should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce risk of overdose
Bipolar disorder
- A major depressive episode may be the initial presentation of bipolar disorder; it is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder
- Whether any of the depressive symptoms represent a conversion is unknown; however, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression; the drug is not approved for use in treating bipolar depression
Serotonin syndrome
- The development of a potentially life-threatening serotonin syndrome has been reported with serotonin-norepinephrine reuptake inhibitors (SNRIs) and SSRIs alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue)
- Serotonin syndrome symptoms may include mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); patients should be monitored for the emergence of serotonin syndrome
Drug interaction overview
- This drug is capable of blocking antihypertensive effect of guanethidine and similarly acting compounds
- In patients who may use alcohol excessively, the potentiation may increase the danger inherent in any suicide attempt or overdosage
Pregnancy & Lactation
Pregnancy
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy
Healthcare providers are encouraged to register patients by calling the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or visiting online at http://womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants
Safe use during pregnancy has not been established; therefore, if it is to be given to pregnant patients or women of childbearing potential, the possible benefits must be weighed against possible hazards to mother and child
Animal reproductive studies have been inconclusive
Lactation
Safe use during lactation has not been established; therefore, if it is to be given to pregnant patients, nursing mothers, or women of childbearing potential, the possible benefits must be weighed against possible hazards to mother and child
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Neurotransmitter (esp NE & serotonin) reuptake inhibitor; inhibits reuptake by neuronal membrane; may also downregulate beta-adrenergic receptors and serotonin receptors
Pharmacokinetics
Half-Life elimination: 15-24hr
Onset: 2-5 days (initial therapeutic effect); 2-3 wk (full effect)
Peak Plasma Time: 4-6 hr
Excretion: Urine (70%)
Metabolism: Hepatic CYP2D6
Metabolites: 2-hydroxydesipramine
Images
BRAND | FORM. | UNIT PRICE | PILL IMAGE |
---|---|---|---|
Norpramin oral - | 25 mg tablet | ![]() | |
Norpramin oral - | 10 mg tablet | ![]() | |
desipramine oral - | 10 mg tablet | ![]() | |
desipramine oral - | 10 mg tablet | ![]() | |
desipramine oral - | 150 mg tablet | ![]() | |
desipramine oral - | 75 mg tablet | ![]() | |
desipramine oral - | 50 mg tablet | ![]() | |
desipramine oral - | 25 mg tablet | ![]() | |
desipramine oral - | 75 mg tablet | ![]() | |
desipramine oral - | 25 mg tablet | ![]() | |
desipramine oral - | 10 mg tablet | ![]() | |
desipramine oral - | 150 mg tablet | ![]() | |
desipramine oral - | 100 mg tablet | ![]() | |
desipramine oral - | 75 mg tablet | ![]() | |
desipramine oral - | 50 mg tablet | ![]() | |
desipramine oral - | 25 mg tablet | ![]() | |
desipramine oral - | 10 mg tablet | ![]() | |
desipramine oral - | 150 mg tablet | ![]() | |
desipramine oral - | 10 mg tablet | ![]() | |
desipramine oral - | 150 mg tablet | ![]() | |
desipramine oral - | 75 mg tablet | ![]() | |
desipramine oral - | 50 mg tablet | ![]() | |
desipramine oral - | 100 mg tablet | ![]() | |
desipramine oral - | 25 mg tablet | ![]() | |
desipramine oral - | 25 mg tablet | ![]() | |
desipramine oral - | 50 mg tablet | ![]() | |
desipramine oral - | 100 mg tablet | ![]() | |
desipramine oral - | 150 mg tablet | ![]() | |
desipramine oral - | 100 mg tablet | ![]() | |
desipramine oral - | 75 mg tablet | ![]() | |
desipramine oral - | 50 mg tablet | ![]() | |
desipramine oral - | 100 mg tablet | ![]() |
Copyright © 2010 First DataBank, Inc.
Patient Handout
desipramine oral
DESIPRAMINE - ORAL
(des-IP-ra-meen)
COMMON BRAND NAME(S): Norpramin
WARNING: Antidepressant medications are used to treat a variety of conditions, including depression and other mental/mood disorders. These medications can help prevent suicidal thoughts/attempts and provide other important benefits. However, studies have shown that a small number of people (especially people younger than 25) who take antidepressants for any condition may experience worsening depression, other mental/mood symptoms, or suicidal thoughts/attempts. It is very important to talk with the doctor about the risks and benefits of antidepressant medication (especially for people younger than 25), even if treatment is not for a mental/mood condition.Tell the doctor right away if you notice worsening depression/other psychiatric conditions, unusual behavior changes (including possible suicidal thoughts/attempts), or other mental/mood changes (including new/worsening anxiety, panic attacks, trouble sleeping, irritability, hostile/angry feelings, impulsive actions, severe restlessness, very rapid speech). Be especially watchful for these symptoms when a new antidepressant is started or when the dose is changed.
USES: Desipramine is used to treat depression. This medication may improve your mood, sleep, appetite, and energy level and may help restore your interest in daily living. This medication belongs to a class of medications called tricyclic antidepressants. It works by restoring the balance of a certain natural substance (norepinephrine) in the brain.This drug is not recommended for use in children younger than 18 years due to risk of serious side effects.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start taking desipramine and each time you get a refill. If you have any questions, ask your doctor or pharmacist.Take this medication by mouth with or without food as directed by your doctor, usually 1 to 3 times daily. The dosage is based on your medical condition and response to treatment. Your doctor may start you at a low dose and gradually increase your dose. This medication may make you sleepy or wakeful. Depending on how this medication affects you, your doctor may direct you to take the entire dose once daily either in the morning or at bedtime.Follow your doctor's instructions carefully. Do not take more or less medication or take it more frequently than prescribed. Your condition will not improve any faster and your risk of side effects will increase. Use this medication regularly in order to get the most benefit from it. To help you remember, use it at the same time(s) each day.Keep taking this medication even if you feel well. Do not suddenly stop taking this medication without consulting your doctor. Some conditions may become worse when the drug is abruptly stopped. Your dose may need to be gradually decreased.This medication does not work right away. It may take 2 to 3 weeks before you experience the full benefits when this medication is used for depression.Inform your doctor if your condition lasts or gets worse.
SIDE EFFECTS: See also Warning section.Headache, nausea, dizziness, drowsiness, nervousness, trouble sleeping, blurred vision, increased appetite, weight gain, constipation and dry mouth may occur. If any of these effects last or get worse, notify your doctor or pharmacist promptly.To reduce the risk of dizziness and lightheadedness, get up slowly when rising from a sitting or lying position.To relieve dry mouth, suck on (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water, or use a saliva substitute.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as confusion, hallucinations, memory problems), enlarged/painful breasts, unusual breast milk production, irregular/painful menstrual periods, ringing in the ears, sexual problems (such as decreased sexual ability, changes in desire), shakiness (tremors), numbness/tingling of the hands/feet, pain/redness/swelling of arms or legs, trouble urinating, easy bruising/bleeding, signs of infection (such as sore throat that doesn't go away, fever), severe stomach/abdominal pain, dark urine, yellowing of eyes/skin.Get medical help right away if you have any very serious side effects, including: chest pain, slow/fast/irregular heartbeat, seizures, fainting, trouble speaking, weakness on one side of the body, eye pain/swelling/redness, widened pupils, vision changes (such as seeing rainbows around lights at night).This medication may increase serotonin and rarely cause a very serious condition called serotonin syndrome/toxicity. The risk increases if you are also taking other drugs that increase serotonin, so tell your doctor or pharmacist of all the drugs you take (see Drug Interactions section). Get medical help right away if you develop some of the following symptoms: fast heartbeat, hallucinations, loss of coordination, severe dizziness, severe nausea/vomiting/diarrhea, twitching muscles, unexplained fever, unusual agitation/restlessness.This drug may rarely cause a serious nervous system disorder (neuroleptic malignant syndrome). Get medical help right away if you notice any of the following very serious side effects: muscle stiffness, high fever, increased sweating, fast heartbeat, sudden mental/mood changes, signs of kidney problems (such as change in the amount of urine).A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: See also Warning section.Before taking this medication, tell your doctor or pharmacist if you are allergic to it; or to other tricyclic antidepressants (such as imipramine, amitriptyline); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (such as asthma, chronic bronchitis), personal or family history of glaucoma (angle-closure type), diabetes, eating disorders (such as bulimia), heart problems (such as arrhythmias, coronary artery disease, heart attack), liver problems, kidney problems, personal or family history of other mental/mood conditions (such as bipolar disorder, schizophrenia), seizures, overactive thyroid (hyperthyroidism), trouble urinating (such as due to enlarged prostate), any condition that may increase your risk of seizures (including alcohol/sedative dependency, use of electroconvulsive therapy, brain injury/disease such as stroke), certain types of tumors (such as pheochromocytoma, neuroblastoma).Desipramine may cause a condition that affects the heart rhythm (QT prolongation). QT prolongation can rarely cause serious (rarely fatal) fast/irregular heartbeat and other symptoms (such as severe dizziness, fainting) that need medical attention right away.The risk of QT prolongation may be increased if you have certain medical conditions or are taking other drugs that may cause QT prolongation. Before using desipramine, tell your doctor or pharmacist of all the drugs you take and if you have any of the following conditions: certain heart problems (heart failure, slow heartbeat, QT prolongation in the EKG), family history of certain heart problems (QT prolongation in the EKG, sudden cardiac death).Low levels of potassium or magnesium in the blood may also increase your risk of QT prolongation. This risk may increase if you use certain drugs (such as diuretics/"water pills") or if you have conditions such as severe sweating, diarrhea, or vomiting. Talk to your doctor about using desipramine safely.Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Limit alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).This medication may make you more sensitive to the sun. Limit your time in the sun. Avoid tanning booths and sunlamps. Use sunscreen and wear protective clothing when outdoors. Tell your doctor right away if you get sunburned or have skin blisters/redness.If you have diabetes, this drug may make it harder to control your blood sugar. Check your blood sugar regularly as directed and share the results with your doctor. Tell your doctor right away if you have symptoms such as increased thirst/urination. Your doctor may need to adjust your diabetes medication, exercise program, or diet.Older adults may be more sensitive to the side effects of this drug, especially dizziness (more likely when standing up), drowsiness, constipation, trouble urinating, mental/mood changes (such as confusion, agitation) and heart effects such as QT prolongation (see above). Dizziness, drowsiness, and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Infants born to mothers who have taken similar medications during pregnancy may have symptoms such as trouble urinating, prolonged sleepiness, shaking, and seizures. Discuss the risks and benefits with your doctor.Since untreated mental/mood problems (such as depression, panic disorder) can be a serious condition, do not stop taking this medication unless directed by your doctor. If you are planning pregnancy, become pregnant, or think you may be pregnant, immediately discuss with your doctor the benefits and risks of using this medication during pregnancy.This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: disopyramide, certain drugs for high blood pressure (such as clonidine, guanadrel, guanethidine), digoxin, thyroid supplements, valproic acid.Taking MAO inhibitors with this medication may cause a serious (possibly fatal) drug interaction. Avoid taking MAO inhibitors (isocarboxazid, linezolid, metaxalone, methylene blue, moclobemide, phenelzine, procarbazine, rasagiline, safinamide, selegiline, tranylcypromine) during treatment with this medication. Most MAO inhibitors should also not be taken for two weeks before and after treatment with this medication. Ask your doctor when to start or stop taking this medication.The risk of serotonin syndrome/toxicity increases if you are also taking other drugs that increase serotonin. Examples include street drugs such as MDMA/"ecstasy," St. John's wort, certain antidepressants (including SSRIs such as fluoxetine/paroxetine, SNRIs such as duloxetine/venlafaxine), among others. The risk of serotonin syndrome/toxicity may be more likely when you start or increase the dose of these drugs.Other medications can affect the removal of desipramine from your body, which may affect how desipramine works. Examples include barbiturates (such as phenobarbital), cimetidine, haloperidol, certain drugs for heart rhythm (such as flecainide, propafenone), halofantrine, HIV protease inhibitors (such as fosamprenavir), phenothiazines (such as thioridazine), pimozide, certain anti-seizure drugs (such as phenytoin), antidepressants (such as trazodone), among others.Cigarette smoking decreases blood levels of this medication. Tell your doctor if you smoke or if you have recently stopped smoking.Many drugs besides desipramine may affect the heart rhythm (QT prolongation in the EKG), including amiodarone, dofetilide, pimozide, procainamide, quinidine, sotalol, sparfloxacin, macrolide antibiotics (such as erythromycin), among others. Before using desipramine, report all medications you are currently using to your doctor or pharmacist.Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, marijuana (cannabis), antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), and opioid pain relievers (such as codeine, hydrocodone).Check the labels on all your medicines (such as cough-and-cold products) because they may contain drowsiness-containing ingredients or decongestants that could increase your heart rate or blood pressure. Ask your pharmacist about the safe use of those products.Desipramine is very similar to imipramine. Do not take medications containing imipramine while using desipramine.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe dizziness, fast/irregular heartbeat, fainting, hallucinations, seizures.
NOTES: Do not share this medication with others.Lab and/or medical tests (such as blood count, EKG, kidney function) may be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised April 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.